Mission Therapeutics Raises $15M in Funding

Mission Therapeutics, a Cambridge, England-based drug discovery and development company, raised $15 million in equity funding led by Pfizer Ventures. The company will use the funds to develop its DUB platform and grow its pipeline of DUB inhibitor programs. Mission Therapeutics has also expanded its relationship with Pfizer Inc. by entering into an evaluation and option agreement for DUB target validation.

Mission Therapeutics Secures $15 Million to Advance Deubiquitylating Enzyme Inhibitors

Mission Therapeutics is a Cambridge, England-based drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs). The company intends to use the funds for the development of its DUB platform, as well as growth of its pipeline of DUB inhibitor programmes. Mission has links with key academic and research centers, including Prof. Steve Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and UK centres in neurodegenerative diseases. The company also has secured major industry partnerships, including its collaboration with AbbVie in November 2018, for the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease. 

Mission Therapeutics is a Cambridge-based drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs).

5 years ago

Mission Therapeutics Secures $15 Million to Advance Deubiquitylating Enzyme Inhibitors

ProblemHealthcare

Solution

Covered on